Earnix, the Category Leader in Dynamic AI for the Insurance Industry, Acquires Zelros to Transform Insurers’ Business Performance
29.4.2025 14:10:00 CEST | Business Wire | Press Release
Earnix, the leading Dynamic AI platform for Insurance, today announced that it has signed a definitive agreement to acquire Zelros, a pioneer in Generative AI for insurers and banks. This innovative collaboration will bring the power of predictive, generative, and agentic AI across the entire risk decisioning, personalization, and claims cycle, thereby enabling pricing and underwriting professionals to deliver compelling offers while improving business performance.
By combining Earnix’s advanced Predictive AI platform with Zelros’s GenAI recommendations engine, providers can now present the right offer, at the right price, at the right time. The joint offering provides precise decision-making at scale in regulated environments for pricing and product managers, underwriters, and agents, ultimately resulting in higher conversion rates with better customer engagement and satisfaction.
Both companies bring demonstrated impact in supporting leading insurers and banks across the globe, including Aviva, AXA, BPCE, IAG, Generali, Matmut, Santander, and Tokio Marine. "As a mutual customer of Zelros and Earnix, we’re excited about the acquisition,” shared Stéphane Muller (Chief Insurance Officer) and David Quantin (Chief Information Officer) of Matmut. “The synergies between the two are compelling and will help us better meet our members' coverage needs and experiences."
"We are pleased to announce Earnix’s acquisition of Zelros, a strategic move that reaffirms us as the technology leader driving responsible AI innovation,” cited Robin Gilthorpe, CEO of Earnix. “Furthermore, we are strengthening our presence in France by establishing a key development center for the company in this critical market. We are excited about this new chapter and the immense potential it unlocks for our customers and partners."
“With the integration of our leading predictive and generative AI capabilities, we aim to reshape the customer experience by providing personalized, data-driven interactions that build confidence and drive retention,” added Damien Philippon, Co-founder and CEO of Zelros. “Our shared commitment to continuous innovation ensures that together, Earnix and Zelros will lead the way in delivering best-in-class solutions for the insurance and banking sectors.”
Dr. Erel Margalit, the Chairman of Earnix and multiple other innovative companies, including, formerly, CyberArk (Nasdaq: CYBR), says “Over the last few years, Earnix has established itself as the preeminent AI platform for Pricing, Rating, and Insurance Operations across more than 35 countries. Working with core systems providers, such as Guidewire, Earnix is the complementary AI platform which allows for dynamic, data-driven responses to changing market conditions. France has been a key focus for us as we expand our European operations, and we are delighted to have Zelros and the team join us in Paris.”
Earnix and Zelros are committed to reshaping the future, driving innovation that delivers business impact. This acquisition represents a significant leap forward in harnessing the full power of AI designed specifically to meet the evolving demands of insurers, banks, and the customers they serve.
About Earnix
Earnix is the premier provider of mission-critical, intelligent decisioning across pricing, underwriting, rating, and product personalization. Its fully integrated platform provides ultra-fast ROI and is designed to transform how global insurers and banks are run by unlocking value across all facets of the business. Earnix has been innovating for insurers and banks since 2001, with customers in over 35 countries across six continents and offices in the Americas, Europe, Asia Pacific, and Israel. Earnix is backed by investors JVP and Insight Partners.
To learn more, visit: www.earnix.com.
About Zelros
Zelros is a pioneer and award-winning InsurTech. Its GenAI-driven recommendation engine is transforming insurance distribution by enabling a unique customer and agent experience through hyper-personalized insurance recommendations across channels. Zelros is trusted by some of the world’s largest insurance companies, including AXA, BPCE, Groupe Prévoir, MAIF, and Matmut, to help them stay competitive, boost client acquisition and satisfaction, and adhere to Responsible AI governance.
More information on: www.zelros.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250429126257/en/
Contacts
Media Relations, Earnix
press@earnix.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom